Doubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy.
Journal
Case reports in urology
ISSN: 2090-696X
Titre abrégé: Case Rep Urol
Pays: United States
ID NLM: 101580193
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
11
2019
revised:
26
02
2021
accepted:
10
03
2021
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
epublish
Résumé
The utility of serial Decipher biopsy scores in a true active surveillance population is still unknown. In a man on active surveillance for low-risk prostate cancer, a doubling of the Decipher biopsy score within genomic low-risk category from first to the second biopsy related to biopsy reclassification to Gleason grade group 4 on the third biopsy. However, the final pathology at radical prostatectomy showed Gleason grade group 2 with an organ-confined disease. This case suggests that the genomic risk category of Decipher biopsy scores during active surveillance may be more informative than either the interval genomic score change or the biopsy Gleason grade group.
Identifiants
pubmed: 33936831
doi: 10.1155/2021/2687416
pmc: PMC8054861
doi:
Types de publication
Case Reports
Langues
eng
Pagination
2687416Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
Copyright © 2021 Kamyar Ghabili et al.
Déclaration de conflit d'intérêts
Preston Sprenkle serves as a consultant for Boston Scientific and GenomeDx Biosciences.
Références
J Urol. 2019 Oct;202(4):696-701
pubmed: 30958742
Urology. 2019 Mar;125:64-72
pubmed: 30552940
Eur Urol. 2015 Apr;67(4):619-26
pubmed: 25457014
Transl Androl Urol. 2018 Feb;7(1):155-159
pubmed: 29594029
Eur Urol Focus. 2021 Jan;7(1):47-54
pubmed: 31147263
Urol Clin North Am. 2016 Feb;43(1):7-15
pubmed: 26614025